Cited by 58Down syndrome and intellectual disability researchNeuroscience and Neuropharmacology ResearchGenetics and Neurodevelopmental Disorders

Glutamatergic Transmission Aberration: A Major Cause of Behavioral Deficits in a Murine Model of Down's Syndrome

Open access
Kaur, Gurjinder, Sharma, Ajay, Xu, Wenjin, Gerum, Scott, Alldred, Melissa J., Subbanna, Shivakumar, Basavarajappa, Balapal S., Pawlik, Monika +5 more·2014·The Journal of Neuroscience

Abstract

Trisomy 21, or Down's syndrome (DS), is the most common genetic cause of intellectual disability. Altered neurotransmission in the brains of DS patients leads to hippocampus-dependent learning and memory deficiency. Although genetic mouse models have provided important insights into the genes and mechanisms responsible for DS-specific changes, the molecular mechanisms leading to memory deficits are not clear. We investigated whether the segmental trisomy model of DS, Ts[Rb(12.1716)]2Cje (Ts2), exhibits hippocampal glutamatergic transmission abnormalities and whether these alterations cause behavioral deficits. Behavioral assays demonstrated that Ts2 mice display a deficit in nest building behavior, a measure of hippocampus-dependent nonlearned behavior, as well as dysfunctional hippocampus-dependent spatial memory tested in the object-placement and the Y-maze spontaneous alternation tasks. Magnetic resonance spectra measured in the hippocampi revealed a significantly lower glutamate concentration in Ts2 as compared with normal disomic (2N) littermates. The glutamate deficit accompanied hippocampal NMDA receptor1 (NMDA-R1) mRNA and protein expression level downregulation in Ts2 compared with 2N mice. In concert with these alterations, paired-pulse analyses suggested enhanced synaptic inhibition and/or lack of facilitation in the dentate gyrus of Ts2 compared with 2N mice. Ts2 mice also exhibited disrupted synaptic plasticity in slice recordings of the hippocampal CA1 region. Collectively, these findings imply that deficits in glutamate and NMDA-R1 may be responsible for impairments in synaptic plasticity in the hippocampus associated with behavioral dysfunctions in Ts2 mice. Thus, these findings suggest that glutamatergic deficits have a significant role in causing intellectual disabilities in DS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.5338-13.2014

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Extensive characterization of adult Ts2 mice has documented neuropathological abnormalities equivalent in type and onset to those in the Ts65Dn trisomy model of DS.

    “Extensive characterization of adult Ts2 mice (Kaur et al., 2014;Hamlett et al., 2016;Jiang et al., 2016) has documented neuropathological abnormalities equivalent in type and onset to those in the Ts65Dn trisomy model of DS”

    From Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) (2019) · cites this paper as Kaur et al., 2014

    The Animals section reports that Ts2 mice were studied at 8 months, and the Discussion documents hippocampal glutamatergic and synaptic abnormalities. The Introduction describes synaptic plasticity and neurotransmitter abnormalities in Ts65Dn mice, but the paper does not establish that the two models’ neuropathological abnormalities are equivalent in type or onset; it compares Ts2 with disomic controls, not Ts65Dn. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. Alldred MJ, Che S, Ginsberg SD (2008) Terminal Continuation (TC) RNA amplification enables expression profiling using minute RNA input ob- tained from mouse brain. Int J Mol Sci 9:2091-2104. CrossRef Medline · DOI
  2. Alldred MJ, Duff KE, Ginsberg SD (2012) Microarray analysis of CA1 pyra- midal neurons in a mouse model of tauopathy reveals progressive synap- tic dysfunction. Neurobiol Dis 45:751-762. CrossRef Medline · DOI
  3. Bar-Peled O, Gross-Isseroff R, Ben-Hur H, Hoskins I, Groner Y, Biegon A (1991) Fetal human brain exhibits a prenatal peak in the density of sero- tonin 5-HT1A receptors. Neurosci Lett 127:173-176. CrossRef Medline · DOI
  4. Basavarajappa BS, Subbanna S (2014) CB1 receptor-mediated signaling un- derlies the hippocampal synaptic, learning and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus 24:178 -188. CrossRef Medline. · DOI
  5. Best TK, Cramer NP, Chakrabarti L, Haydar TF, Galdzicki Z (2012) Dys- functional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Exp Neurol 233:749 -757. CrossRef Medline · DOI
  6. Bhattacharyya A, McMillan E, Chen SI, Wallace K, Svendsen CN (2009) A critical period in cortical interneuron neurogenesis in Down syndrome revealed by human neural progenitor cells. Dev Neurosci 31:497-510. CrossRef Medline · DOI · Paper page
  7. Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke TA, Goldson EJ, Costa AC (2012) Antagonism of NMDA receptors as a potential treat- ment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2:e141. CrossRef Medline · DOI
  8. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508:333-348. CrossRef Medline · DOI
  9. Canas PM, Simo ˜es AP, Rodrigues RJ, Cunha RA (2014) Predominant loss of glutamatergic terminal markers in a ␤-amyloid peptide model of Alzhei- mer's disease. Neuropharmacology 76:51-56. CrossRef Medline · DOI
  10. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA (2000) Endocytic pathway abnormalities precede amyloid ␤ deposi- tion in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157:277- 286. CrossRef Medline · DOI
  11. Colas D, Chuluun B, Warrier D, Blank M, Wetmore DZ, Buckmaster P, Garner CC, Heller HC (2013) Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro- cognitive benefit in a mouse model of Down's syndrome. Br J Pharmacol 169:963-973. CrossRef Medline · DOI
  12. Costa AC, Scott-McKean JJ, Stasko MR (2008) Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33:1624 -1632. CrossRef Medline · DOI
  13. Cramer N, Galdzicki Z (2012) From abnormal hippocampal synaptic plas- ticity in Down syndrome mouse models to cognitive disability in Down syndrome. Neural Plast 2012:101542. CrossRef Medline · DOI
  14. Danysz W, Parsons CG (2012) Alzheimer's disease, ␤-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br J Pharmacol 167:324 -352. CrossRef Medline · DOI · Paper page
  15. Das I, Reeves RH (2011) The use of mouse models to understand and im- prove cognitive deficits in Down syndrome. Dis Model Mech 4:596 -606. CrossRef Medline · DOI
  16. Deacon RM (2006) Assessing nest building in mice. Nat Protoc 1:1117- 1119. CrossRef Medline · DOI
  17. Deacon RM, Croucher A, Rawlins JN (2002) Hippocampal cytotoxic lesion effects on species-typical behaviours in mice. Behav Brain Res 132:203- 213. CrossRef Medline · DOI
  18. Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A (2013) Amyloid ␤, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci Ther 19:549 -555. CrossRef Medline · DOI
  19. Filali M, Lalonde R (2009) Age-related cognitive decline and nesting behav- ior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 1292:93-99. CrossRef Medline · DOI · Paper page
  20. Filali M, Lalonde R, Rivest S (2011) Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology 60:930 -936. CrossRef Medline · DOI
  21. Ginsberg SD (2008) Transcriptional profiling of small samples in the central nervous system. Methods Mol Biol 439:147-158. CrossRef Medline · DOI
  22. Godridge H, Reynolds GP, Czudek C, Calcutt NA, Benton M (1987) Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry 50:775-778. CrossRef Medline · DOI
  23. Granholm AC, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 161:647-663. CrossRef Medline · DOI
  24. Gruetter R (1993) Automatic, localized in vivo adjustment of all first-and second-order shim coils. Magn Reson Med 29:804 -811. CrossRef Medline · DOI
  25. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Law- rence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C (2012) Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo- controlled trial. Lancet 379:528 -536. CrossRef Medline · DOI
  26. Hanson JE, Weber M, Meilandt WJ, Wu T, Luu T, Deng L, Shamloo M, Sheng M, Scearce-Levie K, Zhou Q (2013) GluN2B antagonism affects in- terneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior. Neuropsychopharmacology 38: 1221-1233. CrossRef Medline · DOI
  27. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC (1996) Developmental abnormalities and age-related neurodegen- eration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A 93:13333-13338. CrossRef Medline · DOI · Paper page
  28. Hughes RN (2004) Responsiveness to brightness change in male and female rats following treatment with the partial agonist of the N-methyl-D-aspartate receptor, D-cycloserine. Behav Brain Res 152:199 -207. CrossRef Medline · DOI
  29. Hynd MR, Scott HL, Dodd PR (2004) Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. J Neurochem 89:240 -247. CrossRef Medline · DOI
  30. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Mu ¨ller-Hill B (1987) The precursor of Alz- heimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736. CrossRef Medline · DOI · Paper page
  31. Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J, Betancur C, El Mestikawy S (2008) Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 29:1619 -1630. CrossRef Medline · DOI
  32. Kirvell SL, Esiri M, Francis PT (2006) Down-regulation of vesicular gluta- mate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 98:939 -950. CrossRef Medline · DOI
  33. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mo- bley WC (2004) Hippocampal long-term potentiation suppressed by in- creased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 24:8153-8160. CrossRef Medline · DOI · Paper page
  34. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC (2012) Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antag- onists. J Neurosci 32:9217-9227. CrossRef Medline · DOI
  35. Levine S, Saltzman A, Levy E, Ginsberg SD (2009) Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. Exp Mol Pathol 86:18 -22. CrossRef Medline · DOI
  36. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC (2011) Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 221:610 -622. CrossRef Medline · DOI
  37. Lott IT, Dierssen M (2010) Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 9:623-633. CrossRef Medline · DOI · Paper page
  38. Luine VN, Jacome LF, Maclusky NJ (2003) Rapid enhancement of visual and place memory by estrogens in rats. Endocrinology 144:2836 -2844. CrossRef Medline · DOI
  39. Macbeth AH, Gautreaux C, Luine VN (2008) Pregnant rats show enhanced spatial memory, decreased anxiety, and altered levels of monoaminergic neurotransmitters. Brain Res 1241:136 -147. CrossRef Medline · DOI
  40. Martínez-Cue ´C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA, Pazos A ´, Flo ´rez J, Gasser R, Thomas AW, Honer M, Knoflach F, Trejo JL, Wettstein JG, Herna ´ndez MC (2013) Reducing GABAA ␣5 receptor-mediated inhibition rescues functional and neuromorphologi- cal deficits in a mouse model of Down syndrome. J Neurosci 33:3953- 3966. CrossRef Medline · DOI
  41. Oka A, Takashima S (1999) The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol 97: 275-278. CrossRef Medline · DOI
  42. Parsons CG, Sto ¨ffler A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53:699 -723. CrossRef Medline · DOI
  43. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L (2003) The neuropsy- chology of Down syndrome: evidence for hippocampal dysfunction. Child Dev 74:75-93. CrossRef Medline · DOI · Paper page
  44. Proctor DT, Coulson EJ, Dodd PR (2010) Reduction in post-synaptic scaf- folding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 21:795-811. CrossRef Medline · DOI
  45. Provencher SW (1993) Estimation of metabolite concentrations from local- ized in vivo proton NMR spectra. Magn Reson Med 30:672-679. CrossRef Medline · DOI
  46. Reisberg B, Doody R, Sto ¨ffler A, Schmitt F, Ferris S, Mo ¨bius HJ (2003) Me- mantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341. CrossRef Medline · DOI · Paper page
  47. Reisberg B, Doody R, Sto ¨ffler A, Schmitt F, Ferris S, Mo ¨bius HJ (2006) A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63:49 -54. CrossRef Medline · DOI
  48. Reynolds GP, Warner CE (1988) Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. Neurosci Lett 94:224 -227. CrossRef Medline · DOI
  49. Risser D, Lubec G, Cairns N, Herrera-Marschitz M (1997) Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 60:1231-1237. CrossRef Medline · DOI
  50. Rueda N, Flo ´rez J, Martínez-Cue ´C (2012) Mouse models of Down syn- drome as a tool to unravel the causes of mental disabilities. Neural Plast 2012:584071. CrossRef Medline · DOI · Paper page
  51. Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, Iizuka R (1986) Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 19:263-269. CrossRef Medline · DOI
  52. Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR (2011) Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging 32:553.e1-511. CrossRef Medline · DOI · Paper page
  53. Scott-McKean JJ, Costa AC (2011) Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by me- mantine. Learn Mem 18:774 -778. CrossRef Medline · DOI
  54. Sheehan R, Ali A, Hassiotis A (2014) Dementia in intellectual disability. Curr Opin Psychiatry 27:143-148. CrossRef Medline · DOI · Paper page
  55. Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z (1999) Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 38:1917-1920. CrossRef Medline · DOI · Paper page
  56. Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, Harashima C, Klann E, Galdzicki Z (2006) Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J Neurochem 98:1266 -1277. CrossRef Medline · DOI · Paper page
  57. Tka ´c I, Starcuk Z, Choi IY, Gruetter R (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41:649 -656. CrossRef Medline · DOI
  58. Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S (2013) Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, ran- domized, clinical trial. J Clin Psychopharmacol 33:636 -642. CrossRef Medline · DOI
  59. Wesson DW, Wilson DA (2011) Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res 216:408 -413. CrossRef Medline · DOI
  60. Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N (2007) Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters crit- ical for normal brain development. Pediatrics 120:e1465-1471. CrossRef Medline · DOI · Paper page
  61. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuro- pathological changes and dementia of Alzheimer's disease in Down's syn- drome. Ann Neurol 17:278 -282. CrossRef Medline · DOI · Paper page
  62. Yates CM, Simpson J, Gordon A (1986) Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. Neu- rosci Lett 65:189 -192. CrossRef Medline · DOI
  63. Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. Annu Rev Physiol 64:355-405. CrossRef Medline · DOI · Paper page

Cited by

Sorted by citations

Authors
Kaur, G., Sharma, A., Xu, W., Gerum, S., Alldred, M. J., Subbanna, S., Basavarajappa, B. S., Pawlik, M., Ohno, M., Ginsberg, S. D., Wilson, D. A., Guilfoyle, D. N., & Levy, E.
Affiliations
Nathan Kline Institute for Psychiatric Research (US)
Venue
The Journal of Neuroscience
Published
2014-04-09
Volume
34
Issue
15
Pages
5099-5106
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W1978078640
Cited by
58
References
7
Citations by year
2025: 6 · 2024: 10 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 6
FWCI
6.30
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Alcohol Abuse and Alcoholism (R01AA019443, AA019443)
  • National Institute on Aging (R01AG037693, AG017617, P01AG017617, AG037693)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
Down syndrome, glutamatergic neurotransmission, NMDA receptor 1, hippocampus, intellectual disability, spatial memory impairment, nest building behavior, synaptic plasticity, dentate gyrus, CA1
MeSH terms
Animals, Disease Models, Animal, Down Syndrome, Female, Male, Memory, Nesting Behavior, Neurons, RNA, Messenger, Synapses, Receptors, N-Methyl-D-Aspartate, Long-Term Potentiation, Glutamic Acid, Maze Learning, Dentate Gyrus, Mice, CA1 Region, Hippocampal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review